Trial Profile
EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Cobicistat/darunavir (Primary) ; Dolutegravir (Primary) ; Abacavir; Atazanavir; Darunavir; Efavirenz; Elvitegravir; Emtricitabine; Etravirine; Lamivudine; Lopinavir; Nevirapine; Raltegravir; Rilpivirine; Ritonavir; Tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Therapeutic Use
- 31 Mar 2022 Status changed from active, no longer recruiting to completed.
- 04 Feb 2021 Planned End Date changed from 1 Dec 2021 to 1 Jun 2023.
- 04 Feb 2021 Planned primary completion date changed from 1 Dec 2021 to 1 Jun 2023.